DK694188D0 - Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel - Google Patents

Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel

Info

Publication number
DK694188D0
DK694188D0 DK694188A DK694188A DK694188D0 DK 694188 D0 DK694188 D0 DK 694188D0 DK 694188 A DK694188 A DK 694188A DK 694188 A DK694188 A DK 694188A DK 694188 D0 DK694188 D0 DK 694188D0
Authority
DK
Denmark
Prior art keywords
combination
application
pharmaceutical preparation
blocking agent
calcium channel
Prior art date
Application number
DK694188A
Other languages
English (en)
Other versions
DK694188A (da
Inventor
Abraham Sudilovsky
Zola Phillip Horovitz
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of DK694188D0 publication Critical patent/DK694188D0/da
Publication of DK694188A publication Critical patent/DK694188A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK694188A 1987-12-14 1988-12-13 Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel DK694188A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13245787A 1987-12-14 1987-12-14
US18882788A 1988-05-02 1988-05-02

Publications (2)

Publication Number Publication Date
DK694188D0 true DK694188D0 (da) 1988-12-13
DK694188A DK694188A (da) 1989-06-15

Family

ID=26830371

Family Applications (1)

Application Number Title Priority Date Filing Date
DK694188A DK694188A (da) 1987-12-14 1988-12-13 Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel

Country Status (9)

Country Link
EP (1) EP0321221A3 (da)
JP (1) JPH0222235A (da)
KR (1) KR890009413A (da)
CN (1) CN1034312A (da)
AU (1) AU623615B2 (da)
DK (1) DK694188A (da)
HU (1) HU206614B (da)
IL (1) IL88502A (da)
PT (1) PT89208A (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU199681B (en) * 1986-11-03 1990-03-28 Sandoz Ag Process for producing new pharmaceutical composition against hypertension and atonic cardiac decomposition
EP0331609A3 (de) * 1988-01-27 1992-07-01 Hoechst Aktiengesellschaft Angiotensin-Converting-Enzym-Hemmstoffe mit psychotroper Wirkung
CA2007525A1 (en) * 1989-01-30 1990-07-30 Zola P. Horovitz Method for facilating dieting employing an ace inhibitor
US5093129A (en) * 1989-01-30 1992-03-03 E. R. Squibb & Sons, Inc. Method for treating addiction to a drug of abuse employing an ace inhibitor
US5089502A (en) * 1989-06-02 1992-02-18 E. R. Squibb & Sons, Inc. Method for preventing or treating anxiety employing a calcium channel blocker
DK0491878T3 (da) * 1989-08-16 1997-06-23 Chiron Corp Præparater til inhibering af proteinhormondannelse og anvendelser deraf
CA2021408A1 (en) * 1989-08-31 1991-03-01 Luana R. C. Moore Method for treating hypermotility diseases of the bowel employing an ace inhibitor and formulation for use therein
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
WO2010110439A1 (ja) * 2009-03-27 2010-09-30 カルピス株式会社 自律神経活動調節用組成物および自律神経を調節する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method

Also Published As

Publication number Publication date
CN1034312A (zh) 1989-08-02
HUT48817A (en) 1989-07-28
AU623615B2 (en) 1992-05-21
IL88502A0 (en) 1989-06-30
EP0321221A2 (en) 1989-06-21
EP0321221A3 (en) 1991-04-03
DK694188A (da) 1989-06-15
HU206614B (en) 1992-12-28
IL88502A (en) 1993-04-04
PT89208A (pt) 1989-12-29
JPH0222235A (ja) 1990-01-25
KR890009413A (ko) 1989-08-01
AU2640488A (en) 1989-06-15

Similar Documents

Publication Publication Date Title
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
DK0450141T4 (da) Bærermateriale til administrering af lægemidler
FI895681A0 (fi) Farmaceutisk komposition foer systemisk transdermal tillfoersel.
NO20053106D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse.
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
DE3778106D1 (de) Dosierungsform mit verzoegernder freisetzung.
NO891893D0 (no) Sementblanding med to faser.
IT1235532B (it) Composti carbossiammidici, procedimenti per la preparazione dei medesimi e composizione farmaceutica contenente i medesimi
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
ES2042776T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
DK694188A (da) Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel
DK23790D0 (da) Doseringsform til administrering af en calciumantagonist
ZA898201B (en) Gestodene-containing agent for transdermal administration
DK665489A (da) Fremgangsmaade til fremstilling af mono-n-alkylerede polyazamakrocykliske forbindelser
DK226488A (da) Anvendelse af ace-inhibitorer til fremstilling af farmaceutiske praeparater
DK586188D0 (da) Kondenserede diazepinoner, fremgangsmaade til deres fremstilling og laegemidler med indhold af saadanne forbindelser
DK99989A (da) Anvendelse af ace-inhibitorer til fremstilling af laegemiddel med profylaktisk virkning mod diabetes
DK524489D0 (da) Fremgangsmaade til fremstilling af biologisk aktive forbindelser, specielt enzymer
DK291189A (da) Kondenserede diazepinoner, fremgangsmaade til fremstilling af saadanne forbindelser og laegemidler med indhold af forbindelserne
ATE71535T1 (de) Pharmazeutische zubereitungen.
BR9809478A (pt) Uso de um oligossacarìdeo sintético, processos para prevenção de coagulação sanguìnea em um mamìfero e para prevenção de coagulação sanguìnea e um circuito sanguìneo extracorpóreo, e, composição farmacêutica adaptada para prevenir coagulação sanguìnea em um circuito sanguìneo extracorpóreo
DK524889D0 (da) Anvendelse af en ace-inhibitor, evt. i kombination med et thrombolytisk middel, til fremstilling af et farmaceutisk praeparat til forbedring af post-ischaemisk myocardial dysfunktion
AR240017A1 (es) Procedimiento de preparacion de una composicion farmaceutica para absorcion percutanea.
HU9501218D0 (en) Use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection
DE68907609D1 (de) Arzneimittelzusammensetzung.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment